For the first time, we demonstrated that high LRIG1 immunoreactivity predicts LNM in cervical cancer patients (adjusted OR 9.49, 95% CI: 1.80–50.05, P = 0.008). This evidence concerns the gene LRIG1 and cervical cancer.